eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.

doi:10.18632/oncotarget.8569

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.

Oncotarget - 10 May 2016

Casadei Gardini Andrea, Marisi Giorgia, Faloppi Luca, Scarpi Emanuela, Foschi Francesco Giuseppe, Iavarone Massimo, Lauletta Gianfranco, Corbelli Jody, Valgiusti Martina, Facchetti Floriana, Della Corte Cristina, Neri Luca Maria, Tamberi Stefano, Cascinu Stefano, Scartozzi Mario, Amadori Dino, Nanni Oriana, Tenti Elena, Ulivi Paola, Frassineti Giovanni Luca

Abstract excerpt

Sorafenib may reduce endothelial nitric oxide synthase (eNOS) activity by inhibiting vascular endothelial growth factor receptors (VEGF-R), leading to a decrease in nitric oxide production. In the Italian multicenter ePHAS (eNOS polymorphisms in HCC and sorafenib) study, we analyzed the role of eNOS polymorphisms in relation to clinical outcome in patients with hepatocellular carcinoma (HCC) receiving sorafenib....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Liver Neoplasms

Share to Niacinamide

Share to Nitric Oxide Synthase Type III

Share to Phenylurea Compounds

Share to Sorafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 27058899
DOI: 10.18632/oncotarget.8569
PMCID: PMC5053704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.PMID 27058899Read ↗

Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.Semantic proximity Read ↗

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.Semantic proximity Read ↗

Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study.Semantic proximity Read ↗

Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with SorafenibSemantic proximity Read ↗

Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.Semantic proximity Read ↗

Genetic biomarkers of sorafenib response in patients with hepatocellular carcinomaSemantic proximity Read ↗

A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.Semantic proximity Read ↗

The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.Semantic proximity Read ↗

Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.Semantic proximity Read ↗

GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.Semantic proximity Read ↗

Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients.Semantic proximity Read ↗

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.